Shares of Bionano Genomics (BNGO) dropped 5.47% in intraday trading on Friday, following an analyst downgrade and concerns about the company's financial performance and restructuring plans.
Ladenburg Thalmann downgraded BNGO to "Neutral" from "Buy," citing the company's Q3 revenue decline of 35% year-over-year and uncertainty around its restructuring efforts. The downgrade suggests that analysts are becoming more cautious about BNGO's near-term prospects.
BNGO's stock plummet also comes amid broader concerns about the company's ability to execute its restructuring plans effectively. The restructuring efforts are seen as critical for the company to improve its financial performance and regain investor confidence.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。